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Abstract
Background: Functional similarity is challenging to identify when global sequence and structure similarity is low. Active-
sites or functionally relevant regions are evolutionarily more stable relative to the remainder of a protein structure and
provide an alternative means to identify potential functional similarity between proteins. We recently developed the FAST-
NMR methodology to discover biochemical functions or functional hypotheses of proteins of unknown function by
experimentally identifying ligand binding sites. FAST-NMR utilizes our CPASS software and database to assign a function
based on a similarity in the structure and sequence of ligand binding sites between proteins of known and unknown
function.
Methodology/Principal Findings: The PrgI protein from Salmonella typhimurium forms the needle complex in the type III
secretion system (T3SS). A FAST-NMR screen identified a similarity between the ligand binding sites of PrgI and the Bcl-2
apoptosis protein Bcl-xL. These ligand binding sites correlate with known protein-protein binding interfaces required for
oligomerization. Both proteins form membrane pores through this oligomerization to release effector proteins to stimulate
cell death. Structural analysis indicates an overlap between the PrgI structure and the pore forming motif of Bcl-xL. A
sequence alignment indicates conservation between the PrgI and Bcl-xL ligand binding sites and pore formation regions.
This active-site similarity was then used to verify that chelerythrine, a known Bcl-xL inhibitor, also binds PrgI.
Conclusions/Significance: A structural and functional relationship between the bacterial T3SS and eukaryotic apoptosis was
identified using our FAST-NMR ligand affinity screen in combination with a bioinformatic analysis based on our CPASS
program. A similarity between PrgI and Bcl-xL is not readily apparent using traditional global sequence and structure
analysis, but was only identified because of conservation in ligand binding sites. These results demonstrate the unique
opportunity that ligand-binding sites provide for the identification of functional relationships when global sequence and
structural information is limited.
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Introduction
Functional regions of a protein are evolutionarily more stable
relative to the remainder of the protein [1,2]. The evolutionary
correlation between ligand binding sites, ligand structure and
protein function has also been demonstrated by a network of
ligand-binding-site similarity described by Park & Kim [3]. A
variety of computational methods have attempted to exploit the
evolutionary stability of functional regions by identifying ligand
binding sites as a method to predict function [4,5]. Unfortunately,
the combined requirements of predicting the ligand, the binding
site, and a similarity to an annotated protein lead to a high level of
ambiguity. Recently, we developed the Functional Annotation
Screening Technology by Nuclear Magnetic Resonance (FAST-
NMR) assay to experimentally identify ligand binding sites to
annotate proteins of unknown function [5–7]. FAST-NMR utilizes
the Comparison of Protein Active Site Structures (CPASS)
software and database to identify similar sequence and structure
characteristics between experimentally identified ligand binding
sites for proteins of known and unknown function [8]. Applying
the FAST-NMR method on previously annotated systems also
enables experimental ligand binding site data to identify functional
relationships that otherwise would not be recognized based solely
on global sequence and structure similarity.
The type three secretion system (T3SS) is composed of 20–25
different proteins, which are assembled in a highly choreographed
mechanism similar to the assembly of flagella [9–11]. In Salmonella
typhimurium, the needle complex is responsible for puncturing a
host’s cell membrane to allow effector proteins (SipB, SipC, SipD)
from S. typhimurium to enter the host [12]. Many of these effectors
can activate bacterial induced apoptosis of a hosts’ cell by
interacting with capsase-1 [13] in a mechanism similar to
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homomultimer composed of ,120 repeated copies of the
monomeric protein PrgI, a small helical protein of 83 amino
acids [15]. The monomeric form of PrgI is a helix-turn-helix motif
with two symmetrically charged surfaces and a conserved loop
region, PxxP domain, which are important for needle assembly
[15–17]. The charged surfaces of PrgI responsible for needle
assembly also provide a potential binding site for small molecule
ligands. This makes PrgI an attractive drug target to disrupt the
formation of the needle complex and prevent infection by S.
typhimurium. However, to date there have been no reported ligands
that bind to either region of this protein-protein interaction site.
The PrgI needle complex protein from S. typhimurium T3SS was
screened in our FAST-NMR assay, which resulted in the
identification of a functional similarity between the ligand binding
sites of PrgI and the anti-apoptosis protein Bcl-xL. Additionally,
Dali [18] and T-Coffee [19] analysis found regions of structure
and sequence similarity between the two proteins consistent with
the FAST-NMR results. The predicted active-site similarity
between PrgI and Bcl-xL was also used to experimentally verify
that chelerythrine [20], a ligand known to inhibit Bcl-xL and
induce apoptosis, also binds PrgI. These results provide experi-
mental evidence that suggest a functional relationship between the
bacterial type III secretion systems and apoptosis. This is
consistent with a general conservation in function between PrgI
and the Bcl-2 family of proteins that includes Bcl-xL; both form
membrane pores through oligomerization using a conserved helix-
turn-helix motif to release effectors to stimulate cell death.
Results
Results from the FAST-NMR screen
The needle complex protein, PrgI, from S. typhimurium is an
attractive antibacterial target because the protein is exposed to the
cell surface and blocking this target could prevent injection of
virulence factors into the host [21]. The interaction of PrgI with
the host membrane stimulates the delivery of effectors from the
bacteria into the host cytosol to induce cell death. Recently an
NMR structure was determined for a monomeric form of PrgI
[15], which enabled the screening of PrgI using the FAST-NMR
assay [6]. FAST-NMR combines NMR ligand affinity screening
[22] using a fragment-based functional library [23] with structural
biology and bioinformatics [8] to rapidly determine protein-ligand
complexes [24] and infer functional relationship between proteins
based on similarities in functional epitopes. Also, the resulting
protein-ligand co-structure provides a valuable starting point for
structure-based drug design.
FAST-NMR applies a tiered approach to screening [22] to
minimize resources and increase throughput (Figure 1). First, PrgI
was screened with the functional chemical library using 1D
1H
NMR line-broadening experiments. Five compounds (L-carnitine
inner salt, didecyldimethylammonium bromide, 1-methylimida-
zole, methiothepin mesylate salt, sucrose) were found to bind PrgI
by showing a significant decrease in
1H peak intensity upon
addition of 25 mM of PrgI. This was determined by comparing
normalized
1H ligand peak intensities between the free and bound
NMR spectra (Figure 1A). However, the secondary 2D
15N-
1H
HSQC experiments identified the lipid derivative didecyldimethy-
lammonium bromide (DDAB) as the only specific PrgI binder
(Figure 1B) based on the observation of a significant number of
chemical shift changes in the spectrum. The remaining four
compounds elicited no change in chemical shifts in the PrgI 2D
15N-
1H HSQC spectrum, which suggest the compounds bound
non-specifically to PrgI. PrgI was found to bind DDAB with a Kd
of 553 mM as calculated by a 1D
1H line broadening method [25].
Finding a lipid derivative that specifically binds to PrgI is
consistent with the protein’s function; sensing new host cells and
signaling secretion through an interaction with the host membrane
[26].
Chemical shift perturbations (CSPs) in the 2D
15N-
1H HSQC
experiments between free PrgI and the complex identified the PrgI
residues that bind DDAB. Mapping these CSPs onto the PrgI
surface identified the DDAB binding site as corresponding to
residues at the bifurcation point of the two helices (Figure 1C).
Specifically, residues S6, L9, S13, K15, and D17 of helix 1 and
N59, V65, K66, V67, F68, K69, D70, D72, A73 and L76 of helix
2 showed significant CSPs in the presence of DDAB as calculated
by equation 1. This ligand binding site has been shown to be
Figure 1. Identification of PrgI Binding Ligands. (A) DDAB NMR spectra in the absence (top) and presence (bottom) of PrgI illustrating changes
in NMR intensities (boxed) upon binding PrgI. Both free and bound 1D
1H NMR spectra were normalized to a constant DMSO signal intensity. (B)
Expanded view of the superimposed 2D
15N-
1H HSQC spectra of the free and DDAB bound PrgI NMR samples. Residues that incur a chemical shift
perturbation are boxed. (C) Expanded view of PrgI surface rendered in VMD [78] where residues that incur a chemical shift change are colored blue
and DDAB is colored yellow. Co-structure based on NMR determined ligand binding site using AutoDock [27] and our AutoDockFilter program [24].
doi:10.1371/journal.pone.0007442.g001
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PrgI forms a repeating coiled-coils structure [10]. According to
recent alanine scanning and structural studies, the surface residues
in the region between the bifurcation point of the two helices and
the conserved loop region, PxxP domain, are important for needle
assembly [15–17]. These residues bind to the backside of the
bifurcation point of the two helices in a stacked N-terminus to C-
terminus manner [15–17].
The PrgI residues exhibiting significant CSPs upon binding
DDAB were used to guide and filter a molecular docking
simulation based on our method to rapidly determine protein-
ligand co-structures [24]. AutoDock 4.0 [27] was used to calculate
100 docked structures within a 3D grid defined by the CSPs. Our
AutoDock Filter program (ADF) selected the best conformer based
on consistency with the magnitude of chemical shift changes [24].
The ligand is expected to be closest to the protein residues that
incurred the largest CSPs. The best PrgI-DDAB docked structure
is shown in Figure 1C, where DDAB adopts an extended
conformation that straddles both helices of PrgI.
Analysis of CPASS and Structure Similarity Results
Comparison of Protein Active Site Structures (CPASS) analysis
of the PrgI-DDAB complex identified a human Bcl-2 protein
family member (the anti-apoptosis regulating protein Bcl-xL (PDB-
ID:1YSN) complexed to an acyl-sulfonamide-based inhibitor
(ABT-737)) [28] as the top hit based on a ligand binding-site
CPASS similarity score of 37.7%. The CPASS alignment is shown
in Figure 2A and is based on maximizing the spatial orientation of
similar residue types between the two ligand-binding sites. All
other proteins with a CPASS similarity .30% were also
evaluated, but Bcl-xL was the only protein that gave a reliable
CPASS score and showed some level of structure or sequence
similarity to PrgI. It is important to note that the CPASS identified
similarity between PrgI and Bcl-xL was fundamentally dependent
on the existence of a Bcl-xL-ligand complex in the PDB. Ligand
complexes for other members of the Bcl-2 protein family (Bax, Bid)
currently do not exist.
While DDAB and ABT-737 are distinctly different ligands, the
compounds share strong similarities in their mode of protein
interactions. ABT-737 binds Bcl-xL edge-on in an elongated
conformation where a minimal number of atoms contact the
hydrophobic binding cleft of Bcl-xL. In this manner, DDAB
mimics this edge contact interaction of ABT-737 with the similar
hydrophobic binding cleft in PrgI. Also, ABT-737 binds in a
protein-protein binding interface similar to DDAB, where
inhibiting protein interactions is the drug’s mechanism of action
Figure 2. Active Site Similarity between PrgI and Bcl-xL. (A) CPASS alignment of the S. typhimurium PrgI active-site complexed to DDAB with
the active-site of human Bcl-2 protein (Bcl-xL) complexed with acyl-sulfonamide-based inhibitor. The residues aligned by CPASS are labeled and
colored blue in the structures. The active site sequence alignment is also shown below the structures. The ligands are colored yellow. (B) Overlay of
the human Bcl-2 protein (red) with S. typhimurium PrgI (turquoise) based on a DaliLite [29] alignment. (C) Multiple-sequence alignment of the three
known T3SS structures of S. typhimurium PrgI, B. pseudomallei BsaL, and S. flexneri MxiH with the human Bcl-2 protein (Bcl-xL). The reliability of the
each amino acid alignment is color-coded from blue (poor) to red (good) using the CORE index [35]. The consensus alignment received a score of 69,
where a perfect alignment receives a score of 100.
doi:10.1371/journal.pone.0007442.g002
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are functionally similar.
A pairwise structure alignment using DaliLite [29] yielded a
non-significant Z-score of 1.4 and only 6% sequence identity
between PrgI (PDB ID:2JOW) and Bcl-xL (PDB ID:1YSN).
Nevertheless, the helix-turn-helix structure of PrgI (residues S13-
V65) overlaps the buried helix-turn-helix motif (N136-I182) in Bcl-
xL that corresponds to helices a5 (residues W137-D156) and a6
(residues L162-D176) (Figure 2B). A focused pairwise comparison
between the full PrgI protein and the a5 and a6 helices of Bcl-xL
gave a low but significant Z-score of 3.3 with a root-mean-square-
difference (rmsd) of 3.1 A ˚. The sequence identity also increases
from 6% to 9% between the full and focused pairwise alignments,
respectively.
While there is an overlap between the DaliLite alignment of
PrgI with Bcl-xL and the protein ligand binding sites identified by
CPASS, these sites are not identical. This arises because the
CPASS similarity is not confined by the primary sequence of the
two proteins, but simply captures the spatial orientation of
conserved residues around a ligand binding site. This is illustrated
by the non-sequential sequence alignment of the PrgI and Bcl-xL
ligand binding sites in Figure 2. The exclusion of the sequence
connectivity as a constraint to determine an alignment illustrates
the advantage of CPASS in identifying a functional relationship
and the limitation of global sequence and structure alignments
such as Dali and BLAST [29,30].
Sequence Similarity Results
A BLAST [30] homology search using the PrgI and Bcl-xL
sequences did not yield any significant information relating PrgI to
Bcl-xL. The Bcl-xL sequence only identified homology to other
Bcl-2 proteins. Similarly, the PrgI sequence was only aligned to
other T3SS needle proteins. This is consistent with a ClustlW2
[31] sequence alignment between PrgI and Bcl-xL that resulted in
a low 14.3% sequence similarity, which falls below the twilight
zone of sequence similarity [32]. Also, focused BLAST searches
did not provide any new information. Searching microbial
genomes using the Bcl-2 sequences or searching the human
genome with T3SS sequences did not identify any sequence
alignments with significant E-values. Thus, global sequence
alignments did not readily result in identifying any relationship
between T3SS and apoptosis proteins. This highlights the power
of active site similarity searches to identify potentially new
functional similarities in proteins.
Hidden Markov model (HMM) methods [33] provide an
alternative and more robust approach to identify homology
between distantly related proteins with low sequence similarity
relative to traditional BLAST searches. The T-Coffee web
server (http://www.tcoffee.org/) providesa consensus sequence
alignment (M-Coffee) using multiple HMM protocols [19]. A
reliable alignment of conserved residues (Figure 2C) was
obtained between the known T3SS structures of PrgI (PDB
ID: 2JOW), BsaL (PDB ID: 2G0U) from Burkholderia pseudomallei,
and MxiH (PDB ID: 2CA5) from Shigella flexneri with the human
Bcl-xL (PDB ID: 1YSN) protein. The multiple-sequence
alignment was obtained using EXPRESSO (3DCoffee) [34]
that combines structural information with a HMM sequence
alignment method. The reliability of the per residue alignment
is color-coded using the CORE index (consistency of overall
r e s i d u ee v a l u a t i o n )[ 3 5 ] ,w h e r et h em a j o r i t yo fr e s i d u e sw e r ei n
the average to good range. The alignment of Bcl-xL with the
three T3SS structures received a CORE index score of 53,
where a score $50 indicates a 90% probability of being
correctly aligned [19]. For comparison, the alignment of the
three known human T3SS proteins resulted in a range of scores
from72 to 76. Thus,PrgI aligns preferentiallyto the otherT3SS
proteins, but its alignment to the pore forming helices in Bcl-xL
is significant and reliable. Importantly, the sequence alignment
of PrgI with Bcl-xL encompasses the same residues involved in
the ligand binding sites identified by CPASS and the structural
similarity identified by DaliLite.
Identification of a Second PrgI Ligand Binding Site
The identification of a compound that binds similarly to both
PrgI and Bcl-xL would further establish a functional relationship
between these two proteins. The BindingDB [36] was used to
identify potential inhibitors of PrgI based on the CPASS predicted
active site similarity with Bcl-xL. A total of 71 ligands were
reported to bind Bcl-xL. A majority of the compounds were
piperazine derivatives and were not readily available. Two
compounds, chelerythrine and sanquinarine were identified as
having affinity to Bcl-xL and were both available from commercial
suppliers. Chelerythrine was selected over sanquinarine based on
previous NMR screening and docking studies that suggested
chelerythrine binds between a4, a5 and a6 of Bcl-xL [37]. This
region of Bcl-xL was predicted to overlap with PrgI based on the
pairwise Dali alignment (Figure 2B). Conversely, sanquinarine
bound the BH3 binding cleft of Bcl-xL and thus was not selected
for this secondary binding analysis [37].
A comparison between the free and chelerythrine bound PrgI
2D
15N-
1H HSQC spectra (Figure 3A) identified a chelerythrine
binding site on PrgI (Figure 3B). The PrgI residues that exhibited
chemical shift changes upon binding chelerythrine include residues
A14, K15 in helix 1 and residues Y57, N59, A60, V65, K66, V67,
F68, and D72 in helix 2. The AutoDock/ADF docked structure of
PrgI with chelerythrine suggests PrgI residues K15 and Y57 are
the most important residues for chelerythrine binding based on a
close contact with the ligand (Figure 3B). Many of the residues that
show significant CSPs for PrgI bound to chelerythrine overlap
with the DDAB residues, however, the chelerythrine binding site is
on the opposite face of PrgI (Figure 4). This indicates that there are
two ligand binding sites on PrgI that is consistent with the two
known protein-protein interaction sites for PrgI self-oligomeriza-
tion. The chelerythrine AutoDock docking energy decreased
significantly compared to DDAB, 20.43 to 25.29 kcal/mol,
respectively.
The binding site of chelerythrine on PrgI is nearly identical to
the binding site of chelerythrine to Bcl-xL (Figure 3C and 3D). In
Bcl-xL, the chelerythrine binding site is described as being
located in the BH groove of helix a4, a5a n da6, which is
composed of residues F131, R132, V135, Y173 and H177
(Figure 3C) [37]. Pairwise structure analysis between PrgI and
Bcl-xL shows that Y173 of Bcl-xL and Y57 on PrgI are
overlapping residues and K15 from PrgI is proximal to V135
from Bcl-xL (Figure 3E). The primary difference between the two
proteins is the lack of a-helix 4 in PrgI, where helix 4 of Bcl-xL
appears to act as a ‘cap’ encasing the ligand and effecting its
relative binding orientation. Chelerythrine binds flat in the PrgI
binding site, while the compound points into the corresponding
Bcl-xL binding site partially overlaying helix a4. Again, both of
these structures are docked models based on NMR CSPs and
require a high-resolution x-ray or NMR structure to confirm the
conformation of the chelerythrine binding site. It is paramount to
note that this similarity in chelerythrine binding between the two
proteins would have not been discovered if it was not for the
identification of the initial conserved ligand binding site between
PrgI and Bcl-xL using the FAST-NMR method in combination
with the CPASS database.
T3SS and Apoptosis Similarity
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Ligand Binding Similarity of the Bcl-2 Family of Proteins
with PrgI
A structural and functional similarity between PrgI, a type three
secretion system protein, and Bcl-xL, a member of the Bcl-2 family
of proteins involved in eukaryotic apoptosis, was identified from a
FAST-NMR ligand affinity screen in combination with a bioinfor-
matic analysis. This association is fundamentally based on the
similarity in ligand binding sites depicted in Figure 2A, where the
conserved helix-turn-helix motif simply provides secondary support
of a PrgI and Bcl-2 functional link. While similar active sites provide
a measure of functional similarity, inferring homology based solely
on the observation ofa similar helix-turn-helix motifis questionable.
The helix-turn-helix is a common motif and without a global
sequence similarity, an evolutionary lineage based solely on active
site similarity cannot be readily established. However, identifying
similar ligand-binding sites between the two proteins does provide
support that the proteins share a common function and are
expected to bind similar ligands.
The initial identification of the conserved DDAB ligand binding
site between Bcl-xL and PrgI was used to predict, test and confirm
that chelerythrine binds PrgI in a similar manner to Bcl-xL. This
further supports the structural and functional similarity between
PrgI and Bcl-xL, but also demonstrates the utility of active site
similarity as a predictive tool for ligand binding. Chelerythrine was
Figure 3. Verification that the Bcl-xL inhibitor chelerythrine also binds PrgI. (A). Expanded overlay of the 2D
15N-
1H HSQC spectra for free
PrgI (black) and PrgI bound to chelerythrine (blue). CSPs greater than one standard deviation are boxed. (B) An AutoDock/ADF docked structure of
PrgI complexed with chelerythrine based on the observed CSPs from (A). (C) The Bcl-xL region shown to bind chelerythrine is highlighted while the
remaining protein structure is transparent. Chelerythrine is colored yellow and is drawn with licorice bonds. Side-chains for Y173 and V135 are shown
as licorice bonds and colored grey. (D) A ribbon diagram of the AutoDock/ADF docked PrgI-chelerythrine co-structure. The PrgI-chelerythrine binding
region that overlaps with Bcl-xL is highlighted. Chelerythrine is colored yellow and is drawn with licorice bonds. Side-chains for Y57 and K15 are
shown as licorice bonds and colored grey. (E) An expanded view of the overlay of Bcl-xL (red) with PrgI (blue) illustrating the structural similarity of
the chelerythrine binding sites.
doi:10.1371/journal.pone.0007442.g003
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similarity with Bcl-xL. Thus, these studies have identified the first
known ligands to bind PrgI (DDAB and chelerythrine). Both ligand
bindingsitesareassociated withthefunctionallyimportant PrgI self-
oligomerization sites. Therefore, compounds based on either the
DDAB or chelerythrine scaffold may disrupt PrgI oligomerization.
These compounds may serve as valuable chemical leads to develop
novel antibiotics. Additionally, since the ligands bind in separate
locations on the PrgI surface (Figure 4), the compounds present two
distinct approaches for developing drugs targeting PrgI. Unfortu-
nately, because chelerythrine also binds Bcl-xL it is reasonable to
expect that an antibiotic designed using chelerythrine as a scaffold
may produce undesirable off-target side effects. This issue may be
minimized or eliminated by simply improving the PrgI binding
affinity for chelerythrine derivatives. This illustrates another
important feature of our FAST-NMR protocol; active site similarity
is a useful tool to predict potential side effects due to off target
inhibition, in addition to predicting potential drug leads. While
computational methods for predicting potential drug toxicity [38]
are useful because of their speed, validation requires experimental
methods such as the FAST-NMR approach.
Functional Similarity of the Bcl-2 Family of Proteins with
PrgI
The Bcl-2 family of proteins are essential for eukaryotic
apoptosis; where Bcl-xL is responsible for repressing cell death
activity [14]. The in vivo binding partners of Bcl-xL include the
pro-apoptosis proteins Bax, Bak and Bid. It has been shown that
expression levels of repressor (Bcl-xL) and pro-apoptosis proteins
(Bax, Bak and Bid) are reciprocal in nature suggesting precise
regulation of eukaryotic apoptosis [39]. A combination of
mutational and structure based work has shown that the BH3
binding domain of Bcl-xL is critical for binding interactions with
other Bcl-2 proteins and apoptosis regulation [39].
The structure of Bcl-xL very closely resembles the structures of
Bax, Bid, Bcl-2, and other members of the Bcl-2 family of proteins,
which all resemble pore-forming domains of bacterial toxins
[40–42]. Bcl-2, Bcl-xL, Bax and the truncated active form of Bid
(tBid) have all been shown to form pores in liposomes, but a similar
cellular function has only been observed for Bax [39,43,44]. In
healthy cells, Bax is a monomer in the cytosol. Many different
apoptotic signals result in the transfer of Bax to the outer
mitochondrial membrane where an interaction with Bid and the
lipid membrane induces Bax to form a supramolecular opening in
the outer mitochondrial membrane [45,46]. This pore structure
causes the release of pro-apoptotic factors from the mitochondria
into the cytoplasm to induce cell death [47] and contains ,22
copies of Bax with a diameter of ,20 nm. The interaction of Bcl-
xL with Bax prevents Bax induced cell death [48], where drugs
that disrupt Bcl-xL interacting with Bcl-2 proteins are a promising
form of cancer therapy [49]. Bcl-xL has been described as a
dominant-negative version of Bax [50].
PrgI comprises the T3SS needle structure, which is formed by a PrgI
homomultimer composed of ,120 copies of the protein [9–11]. This
needle structure senses and punctures host membranes forming a pore
to transfer proteins to induce cell death in a mechanism similar to
eukaryotic apoptosis [12–14]. A general conservation in function
between PrgI and the Bcl-2 protein family is readily apparent; both
form membrane pores via a helix-turn-helix motif through oligomer-
ization to release effectors to stimulate cell death. Additionally, PrgI
requires PrgJ for oligomerization into the needle [10] while Bax
requires Bid to induce pore formation [46]. Thus, a protein interaction
with other members of the Bcl-2 family is required to either promote
(Bid) or inhibit (Bcl-xL) Bax oligomerization. It is also interesting that
PrgI was found to bind to a lipid analog and lipids have been found to
play a role in Bax oligomerization [46].
Importantly, the experimentally observed ligand-binding sites
for both PrgI and Bcl-xL are functionally equivalent and within
the conserved helix-turn-helix motif. Both sites correspond to
functionally critical protein-protein interaction sites required for
oligomerization and pore formation. The DDAB binding site on
PrgI overlaps with key residues involved in PrgI oligomerization
and needle assembly. Similarly, ABT-737 is an inhibitor of
apoptosis and functions by inhibiting Bcl-xL protein interactions
[51]. Thus, the similarity in the ligand-binding sites helps establish
a functional link between the two proteins.
Structural Similarity of the Bcl-2 Family of Proteins with
PrgI
The Bax pore-forming domain is conserved in Bcl-xL, Bcl-2 and
Bid [40,52] and corresponds to the helix-turn-helix motif (helices
a5 and a6) that was identified by CPASS to be similar to PrgI
Figure 4. The two PrgI ligand binding sites identified using FAST-NMR. The two PrgI ligand binding sites are highlighted on an electrostatic
potential surface (blue positive charge, red negative charge) calculated with DelPhi [79] implemented in Chimera [80]. The didecyldimethylammonium
bromide binding site (A) is found in a region responsible for needle formation while the chelerythrine binding site (B) is found on the opposite face.
doi:10.1371/journal.pone.0007442.g004
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by DaliLite resulted in the alignment of the PrgI structure with this
conserved Bcl-2 helix-turn-helix motif (Figure 2B). Additionally, a
multiple sequence alignment indicated a reliable similarity
between T3SS needle-forming proteins and the Bcl-2 pore-
forming region (Figure 2C). Thus, the PrgI structure can be
viewed as a minimalistic version of the Bcl-2 structure, and it
corresponds to the functionally essential and conserved core pore-
forming domain.
Gene duplication along with insertion and/or deletions of sub-
structures into variable genetic regions are known methods for the
evolution of protein function [53,54]. These processes may explain
the evolution of the Bcl-2 family of proteins from a smaller PrgI-
like ancestor. Since the PrgI structure overlaps with residues N136
to I182, this may suggest N- and C-terminal insertions generated a
Bcl-2 protein from a PrgI-like ancestor. This is consistent with the
hypothesis proposed by Aouacheria et al. [55], where the ancestral
toxic pore forming domain (helices a5 and a6) required
developing a means to prevent inappropriate apoptosis and to
regulate cell death.
Presumably, a main function of the N- and C-terminal inserts into
a PrgI-like ancestor would be to stabilize the monomer form of Bax
untilanapoptoticsignaloccurs.Ineffect,theinsertionswouldprovide
a stronger control over the pore formation process. This is consistent
with what has been experimentally observed, both the N- terminus
and C-terminus residues of Bax are essential to maintain the
monomer form of Bax in the cytosol [42,56,57]. Deletion of the first
20 amino acids from the N-terminus results in Bax being localized to
the mitochondria [56,57]. Similarly, the Bax structure indicates the
C-terminal hydrophobic helix a9 is bent in a hydrophobic groove,
but contains some critical solvent exposed polar residues that are
necessary to maintain solubility [42]. In fact, a model for the
translocation of Bax from the cytosol to the mitochondria requires a
conformational change in Bax that opens up helixa9a n de x p o s e st h e
pore forming region composed of helices a5a n da6 [42,58].
Deletions of 21 residues from the C-terminus, which includes part of
helix a6, prevents oligomerization [59].
While Bax oligomerizes to form a circular pore structure
containing ,22 copies, this oligomerization process does not
extend to form layers like the PrgI needle structure. The
conformational change in Bax results in the globular domain
remaining in the cytosol and sterically prevents oligomerization
perpendicular to the membrane [60]. Thus, the structural insert
that maintains a monomer Bax in the cytosol also prevents an
unnecessary linear extension of the Bax oligomer out of the
mitochondria membrane. Conversely, regulating PrgI oligomeri-
zation is not necessary since the assembly of the T3SS system is
not detrimental to the cell. Therefore, a minimal pore-forming
structure is all that is necessary for the T3SS system. The length of
the PrgI needle is controlled by the proper assembly of the inner
rod (PrgJ) that requires the InvJ protein [61]. The deletion of InvJ
results in long non-functional needles.
An Evolutionary Relationship between T3SS and
Eukaryotic Apoptosis?
Based on the observed similarity in the structure and function
between PrgI and the Bcl-2 protein family it is tempting to
hypothesize that the proteins share a common ancestor. The
structural comparison of PrgI with the Bcl-2 family of proteins
discussed above suggests a possible evolutionary path. A common
ancestral protein has been suggested for the Bcl-2 protein family,
where pore formation using helices a5 and a6 is the ancestral
protein’s predicted primary function [55]. Similarly, T3SS are also
predicted to evolve from a single gene [62] that is a simple but
versatile export system [63]. Again, the helix-turn-helix is a
common and ancient motif [64] demonstrating both its diverse
utility and evolutionary stability. Thus, it is plausible that a simple
and ancient PrgI-like protein could be an evolutionary precursor
to both the Bcl-2 protein family and PrgI. It also appears unlikely
that PrgI and the Bcl-2 protein family would evolve through a
convergent process since the helix-turn-helix is such a simple and
ancient motif [64] and essential to the function of both proteins.
Evolving a readily available helix-turn-helix protein into either
PrgI or the Bcl-2 protein family seems like a simpler path than the
conversion of a uniquely distinct fold to incorporate a core helix-
turn-helix motif. Also, the evolution of proteins from simple
structural components has been previously proposed [65] and is
consistent with other general evolutionary trends where complex
systems evolve from simpler systems [66].
By analogy, the sharing of a common ancestor by PrgI and the
Bcl-2 family of proteins would imply an evolutionary relationship
between the T3SS and eukaryotic apoptosis systems. T3SS is a
prime example of a vestigial system and an important illustration
of the stepwise evolution of the flagella machinery [67,68].
Therefore, it is reasonable to expect that other systems will be
identified that share an evolutionary relationship with T3SS. T3SS
is also an ancient system and clearly predates the origin of the
mitochondria from prokaryote endosymbiosis [69,70]. a-proteo-
bacteria [69], which are close relatives of the mitochondria, are
known to contain T3SS [63,71,72]. Could an obsolete T3SS
system contribute valuable components to the eukaryotic apoptosis
system after endosymbiosis? An evolutionary link has already been
observed between a mitochondrial and T3SS protein [73,74].
Furthermore, a detailed analysis of the origin of apoptotic proteins
suggests a pivotal role for bacterial proteins in the evolution of
eukaryotic apoptosis [75].
Materials and Methods
FAST-NMR Screen of PrgI
The Salmonella typhimurium type three secretion protein (T3SS)
PrgI was screened with a functional library [23] using our FAST-
NMR assay [5,6]. Unlabeled and
15N labeled monomeric PrgI was
graciously provided by Dr. Roberto DeGuzman (University of
Kansas) along with the assigned
15N-
1H HSQC spectrum. Sample
preparation and experimental parameters for the NMR screening
were executed in the same manner as described previously [6]. A
total of 113 1D
1H NMR line-broadening spectra were collected
to identify 5 binders from the functional chemical library of 437
compounds. Measurement of binding dissociation constants were
completed as described previously [25]. Secondary 2D
15N-
1H
HSQC NMR experiments were collected only for the 5
compounds identified as binders in the line-broadening experi-
ments. Chemical shift perturbations (CSPs) (eq 1) from the 2D
15N-
1H HSQC NMR experiments were used to identify the PrgI
ligand binding site, where only residues with a CSP greater than
one standard deviation from the mean were used:
CSP~
DNH ðÞ
2z
D15N
5
   2
2
2
6 6 6 4
3
7 7 7 5
1=2
ð1Þ
where DNH is the difference between free and bound
1H amide
chemical shifts (ppm) and D15N is the difference between free and
bound
15N chemical shifts (ppm).
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was employed to determine a PrgI co-structure in the same
manner as described previously [24]. The CSPs minimize the
search space by using a significantly reduced AutoDock 3D grid.
AutoDock 4.0 was used to generate 100 docked PrgI-ligand co-
structures using the Lamarckian search algorithm with a
population size of 300 and 500,000 energy evaluations [27].
Our AutoDockFilter (ADF) program then uses an NMR energy
function based on the magnitude of CSPs to select the best ligand
conformation.
ENMR~k
X n
i~1
DDist ðÞ
2 DDist~
dcsp dcspvds
0d sƒdcsp
 
ð2Þ
where ADF calculates a pseudo-distance (dCSP) based on the
magnitude of the NH CSP, which is then compared to the shortest
distance (dS) between any atom in the residue that incurred an NH
CSP and any atom in each docked ligand conformer. Comparison
of these CSP-directed and selected ligand-docked structures with
experimental x-ray and NMR structures has yielded an overall
average rmsd of 1.1760.74 A ˚ [24].
A co-structure of the lipid derivative DDAB bound to PrgI was
uploaded to the CPASS database (http://bionmr-c1.unl.edu/
CPASS/cpass.htm) to identify proteins with similar ligand binding
sites by maximizing an rmsd weighted BLOSUM62 [76,77]
scoring function (Sab).
Sab~
X i~n,j~m
i,j~1
dmin
di
e{Drmsdi,j    2
pi,j Drmsdi,j~
rmsdi,j{1r m s d i,jw1A
0
0r m s d i,jƒ1A
0 ð3Þ
(
where active site a contains n residues and is compared to active site
b from the CPASS database which contains m residues, pi,j is the
BLOSUM62 probability for amino-acid replacement for residue i
from active site a with residue j from active site b, Di,j is a corrected
root-mean square differencein the Ca coordinate positions between
residues i and j,a n ddmin/di is the ratio of the shortest distance to
the ligand among all amino-acids in the active site compared to the
current amino-acid’s shortest distance to the ligand. Sab is only
summed over the optimal alignment for residue i from active site a
with residue j from active site b. It is not summed over all possible
combinations of i and j. If the number of residues are not identical
between active sites a and b (n?m), then the additional residues will
not have a corresponding match. Each residue can only be used
once in the alignment. If active site a contains unmatched residues,
then no contribution is made to Sab which effectively reduces the
maximal possible score that can be achieved for active site a.
Currently, there are ,35,000 protein-ligand structures in the
CPASS database. CPASS runs on a 16 node Beowulf Linux cluster,
requires approximately 40 sec for each pair-wise comparison and
takes ,24 hrs to complete a full search against the entire database.
Structure Similarity Searching
Native protein structures for PrgI (PDB ID: 2JOW) [15] and Bcl-
xL (PDB ID: 1YSN) [28] were uploaded to the DaliLite [29] web
server (http://www.ebi.ac.uk/DaliLite/) to identify regions of
structure homology between the two proteins. To identify structure
similarity and possible homologies between other proteins within
the PDB, the structures were also uploaded to the full Dali [18] web
server (http://www.ebi.ac.uk/dali/).A truncated version of the Bcl-
xL structure was generated by identifying the amino acids within
regions of structure similarity and removing these residues from the
native PDB file. The truncated PDB file was searched for regions of
similarity using the DaliLite web server (http://www.ebi.ac.uk/
Tools/dalilite/index.html).
Sequence Similarity Searching using BLAST and T-Coffee
Sequences from the T3SS and apoptosis regulation were
downloaded from the NCBI server (http://www.ncbi.nlm.nih.
gov/) and included PrgI (gi|16766179), InvJ (gi|16766198) and
InvG (gi|474941) from S. typhimurium, and Bcl-xL, (gi|510901),
Bak1 (gi|82571458), Bid (gi|4557361) and Bax (gi|231632) from
Homo sapiens respectively. A full BLAST search was completed
using these sequences associated with both systems as queries [30].
All BLAST sequence searches used default web settings. In
addition, the sequences and structures for Bcl-xL (PDB-ID:
1YSN), S. typhimurium PrgI (PDB-ID: 2JOW), B. pseudomallei BsaL
(PDB-ID: 2GOU) and S. flexneri MxiH (PDB-ID: 2CA5) obtained
from the PDB were uploaded to the T-Coffee [19] web server
(http://www.tcoffee.org/) to obtain a multiple sequence alignment
using the EXPRESSO(3DCoffee) software [34]. Only the
sequence region of the Bcl-xL structure that contained the pore-
forming domain and yielded the highest alignment score was used
for the multiple sequence alignment.
Secondary Binding Site Similarity between Bcl-xL and
PrgI
To further support a structural and functional similarity between
Bcl-xL and PrgI, the BindingDB [36] (http://www.bindingdb.org/)
was searched for commercially available compounds to test for
binding to PrgI. The free
15N-
1H HSQC spectrum was collected
using 100 mM
15N labeled PrgI in 20 mM bis-Tris buffer with
100 mM sodium chloride at pH 7.0. A second PrgI sample was
prepared in the same manner as above with the addition of 500 mM
chelerythrine to generate the bound
15N-
1H HSQC spectrum.
Chemical shift perturbations and a PrgI-chelerythrine docked co-
structure were determined as described previously [24] and was
compared to the Bcl-xL-chelerythrine model [37].
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